Lecanemab

2022 - 11 - 30

Post cover
Image courtesy of "New Scientist"

Alzheimer's drug lecanemab slows cognitive decline but concerns ... (New Scientist)

The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, ...

Post cover
Image courtesy of "BBC News"

Alzheimer's drug lecanemab hailed as momentous breakthrough (BBC News)

The research breakthrough ends decades of failure and shows a new era of drugs to treat Alzheimer's - the most common form of dementia - is possible. Yet the ...

Post cover
Image courtesy of "NPR"

Study: Alzheimer's drug shows modest success slowing declines in ... (NPR)

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the ...

Post cover
Image courtesy of "Women's Health"

Alzheimer's drug, lecanemab, is declared 'historic' breakthrough (Women's Health)

The first drug to slow signs of Alzheimer's – a type of dementia linked to the brain that affects memory, behaviour and cognition – has been declared a ...

Post cover
Image courtesy of "Sky News"

Lecanemab: New Alzheimer's drug slows decline in memory ... (Sky News)

Results from the clinical trial also revealed that the drug lecanemab cleared clumps of a protein called amyloid - thought to be a key cause of the most common ...

Post cover
Image courtesy of "PharmaTimes"

Eisai and Biogen present promising lecanemab study results (PharmaTimes)

Phase 3 research shows that Alzheimer's disease treatment meets primary and secondary endpoints - News - PharmaTimes.

Post cover
Image courtesy of "CNBC"

Alzheimer's drug trial shown to slow cognitive decline in long fight ... (CNBC)

Results from the clinical trial showed that the medicine lecanemab removed clumps of protein — called beta amyloid — that builds up in brains of people with ...

Post cover
Image courtesy of "European Pharmaceutical Review"

NEJM publishes lecanemab Alzheimer's study results (European Pharmaceutical Review)

Full study results of Eisai's Phase III Alzheimer's study suggest lecanemab could slow disease progression.

Explore the last week